Revolution Medicines, Inc. Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Revolution Medicines, Inc. (RVMD) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $55.93 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2026-02-25
- 2025-12-31: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $55.93M.
- 2024-12-31: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $55.93M.
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $55.93M.
- 2024-06-30: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $55.93M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2025-12-31 | $55.93M 10-K · filed 2026-02-25 |
| 2024-12-31 | $55.93M 10-K · filed 2025-02-26 |
| 2024-09-30 | $55.93M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $55.93M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $55.93M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $55.93M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |